How to Optimize Preclinical Diabetes Studies using Stress Free Methods in Non-Human Primates

Sponsored by:

Crown Bioscience
Date:
April 17, 2019
No items found.

Andrew Puca, PhD presents techniques for optimizing preclinical diabetes research in spontaneously diabetic NHPs, with a focus on stress-free assessments of glucose measurement and response using continuous glucose monitoring and the banana tolerance test.

The key to fighting type 2 diabetes is to develop and utilize novel agents that control multiple disease aspects, rather than individual diabetes components such as hyperglycemia, hypertension, or dyslipidemia alone. To assess new agents, and facilitate faster progression to the clinic, more clinically relevant preclinical models are needed, that mimic full human disease progression.

Non-human primates (NHP) which spontaneously develop diabetes, show all of the characteristics and comorbidities of human type 2 diabetes at different stages of the progressive disease. They provide the most predictive animal model system for preclinical diabetes research, and are combined with novel techniques to reduce invasiveness and stress, leading to improved clinical outcomes and study data.

In this webinar hosted by CrownBio, Dr. Andrew Puca explores unique techniques for optimizing preclinical diabetes research in spontaneously diabetic NHPs. He focuses on stress free assessments of glucose measurement and response in NHPs using continuous glucose monitoring and the banana tolerance test.

Presenters

Andrew Puca

CrownBio
Senior Business Development Director

Dr. Andrew Puca has extensive experience in preclinical drug development, partnering with clients to optimize the translatability of their metabolic disease programs. Since joining CrownBio in 2016, Andrew’s scientific focus has been on translational animal models of cardiovascular and metabolic disease including obesity, type 2 diabetes, NAFLD/NASH, dysmetabolism, and diabetic nephropathy.

Andrew received his Ph.D. in Cellular and Molecular Biology from Università degli Studi di Siena and completed his postdoctoral research at Temple University, specializing in stem cell biology and regenerative medicine. He has over 10 years of translational research experience and has authored 15 publications.

Read More

Sponsor

Crown Bioscience

CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality

Related Content

Related Content